fbpx

molecules of the month

BI-4142

oral HER2 exon 20 mutants selective inhibitor

tumor regression in the HER2YVMA xenograft model

from 12k compounds in-house library screening and opt

Nat. Cancer

Boehringer Ingelheim RCV, Vienna, AT

BI-4142 Chemical Structure oral HER2 exon 20 mutants selective inhibitor - Boehringer Ingelheim RCV, Vienna, AT
5 mins read

Context. BI-4142 (Boehringer Ingelheim) is a HER2 exon 20 insertion mutant inhibitor being developed for non-small cell lung cancer (NSCLC). Despite the general advances made in HER2-targeted therapy and the existence of several agents targeting HER2-positive breast cancer, a high unmet need exists for patients with HER2 mutant NSCLC characterized by oncogenic mutations in exon 20. Approved agents include current EGFR TKIs as well as pan-HER2 TKIs, which are limited in their efficacy due to a lack of selectivity vs. EGFR and EGFR-WT–mediated toxicities which limit effective dosing. In September 2021, the FDA granted accelerated approval to Takeda’s mobocertinib (Exkivity®, a February 2021 MOTM), which targets the related EGFR exon 20 insertion positive NSCLC. BI-4142 was developed as a selective…


request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.


already a member? log in: